What is PT-141?
PT-141 (bremelanotide, brand: Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts centrally on melanocortin receptors in the CNS to increase sexual desire and arousal rather than acting peripherally on blood flow. Administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity. Banned from 503A compounding pharmacies.
Mechanism of Action
Melanocortin MC3R and MC4R agonism in the central nervous system; activates dopaminergic reward pathways and hypothalamic circuits governing sexual behavior; CNS-mediated increase in sexual desire independent of vascular effects
Target: Melanocortin MC3R and MC4R
Research Indications
Research and clinical data supporting effects on sexual response
Clinical data shows improvements in desire and arousal metrics
Acts via central nervous system melanocortin receptor pathways
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | Low dose | Per protocol | Varies |
| Standard Dose | Titrated | Per protocol | Varies |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove PT-141 vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial effects and adaptation period. Monitor for any adverse reactions.
Week 2–4
Primary effects begin to manifest. Adjust dosing as recommended by your provider.
Week 4–8
Main therapeutic effects should be established. Assess progress with your provider.
Week 8+
Evaluate results and determine continuation, cycling, or dose adjustments.
Side Effects & Safety
- Injection site reactions (redness, bruising, mild pain)
- Potential for allergic reaction — discontinue if rash or hives occur
- Individual reactions vary — start at the lowest dose and monitor carefully
- Consult your healthcare provider before use and report any unusual symptoms
PT-141 is banned from 503A compounding pharmacies. Only available through 503B outsourcing facilities or for research use.
FDA Status & Regulatory Info
PT-141 (bremelanotide, brand: Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 acts centrally on melanocortin receptors in the CNS to increase sexual desire and arousal rather than acting peripherally on blood flow. Administered as a subcutaneous autoinjector 45 minutes before anticipated sexual activity. Banned from 503A compounding pharmacies.
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 27 users report
Positive 3% · Neutral 2% · Negative 95%
Most reported benefits
Most reported side effects
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 100 days · Based on 23 repeat reporters
Share Your Experience
Rate PT-141 in the PeptIQ app and help the community make informed decisions.
Research purposes only
This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.